TrialCardiovascular diabetology2025

Weight-independent amelioration of adipokine profile by enavogliflozin, a selective SGLT2 inhibitor, in patients with type 2 diabetes.

Young Sang Lyu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.